Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Both ISS and Glass Lewis Recommend Hudbay Shareholders Vote for Election of Waterton Nominees on the Blue Card

Published

on

Reading Time: 5 minutes

Joins Glass Lewis in Supporting Waterton’s Case for Board Refreshment
and Recommends Shareholders Vote on Waterton’s Blue Proxy Card FOR
Election of
David Smith and Daniel Muniz Quintanilla as Hudbay
Directors

Waterton Urges Fellow Hudbay Shareholders to Vote for All Four of
Waterton’s Independent, Highly-Qualified Nominees to the Board

Vote on the BLUE Proxy and Submit Prior
to 5:00 p.m. (Eastern time) on Thursday May 2, 2019

TORONTO–(BUSINESS WIRE)–Waterton Precious Metals Fund II Cayman, LP (“Waterton Mining LP”) and
Waterton Mining Parallel Fund Offshore Master, LP (“Waterton Fund II”),
each of which are managed by Waterton Global Resource Management, Inc.
(“WGRM,” and collectively with Waterton Mining LP and Waterton Fund II,
“Waterton”), owning in the aggregate 12.09% of the issued and
outstanding common shares (the “Shares”) of Hudbay Minerals Inc.
(“Hudbay” or the “Company”) (TSX:HBM) (NYSE:HBM) today announced that
leading proxy advisory firm Institutional Shareholder Services Inc.
(“ISS”) has joined Glass, Lewis & Co. (“Glass Lewis”) in recommending
that shareholders vote FOR change at Hudbay on Waterton’s Blue proxy
card. ISS recommended the election of Waterton’s independent,
highly-qualified director nominees – David Smith and Daniel Muniz
Quintanilla – to the Hudbay Board of Directors (the “Board”) at the
Annual and Special Meeting of Shareholders (the “Meeting”).

In its report, ISS said the following:1

  • The dissident has highlighted legitimate
    concerns
    around the company’s operational performance and
    capital allocation strategy, which suggest that some degree of board
    change would be beneficial
    .”
  • It appears Hudbay has underperformed the ISS
    Peer Group
    median in terms of ROIC for
    four out of five completed fiscal years
    . While the company has
    recovered after completing its Constancia project, its pre-tax ROIC is
    still below 10 percent and below its WACC.”
  • The company has been trading at a discount to
    peers since early 2016
    , likely reflecting market concerns over
    the return on its substantial capex program and leverage…The substantial
    valuation gap persists
    even after the strong rally in the
    company shares since Oct. 2018.”
  • (I)t seems reasonable to assume that the dissident’s
    emphasis on improving capital allocation played a role in reassuring
    markets
    the company would steer in the right course. This point
    is reinforced when looking at past operational and valuation data.”
  • Dissident nominee Daniel Muniz Quintanilla has extensive experience
    overseeing copper mines in South America and the U.S. Having served as
    at the board and executive level for Southern Copper and Grupo Mexico,
    Muniz has gained experience working for large
    cap companies
    in the industry, which may be beneficial for
    Hudbay as it transitions from a mid-tier to a larger producer.”
  • (S)hareholders are also advised to consider the removal of Kenneth
    Stowe – one of the three incumbents targeted by the dissident, and
    arguably one of the directors most accountable for the company’s past
    performance, given his eight-year tenure.”

Previously, Glass Lewis said:2

  • We are ultimately inclined to suggest the
    Dissident’s core case
     – i.e. that Hudbay has a value
    destructive capital management and project development track record
    and a disconcerting willingness to employ starkly regressive and
    misleading tactics to deter shareholder action — holds
    water here
    .”
  • Indeed, recent and conspicuously-timed rebound notwithstanding, we
    believe the bulk of Hudbay’s performance
    over the last several years demonstrates an objectively substandard
    commitment to preserving and improving shareholder value
    .”
  • [A] closer look suggests all is not well at
    Hudbay
    …a broader review of the Company’s returns suggests
    Hudbay has continually and uniformly lagged its closest industry peers
    across substantially any unaffected measurement period, including
    those falling after completion of Constancia. This trend only appears
    to invert across measurement periods falling after initiation of
    Waterton’s campaign, an unambiguously atypical
    swing which management nevertheless attempts to frame as substantially
    or entirely attributable to Hudbay’s own efforts
    .”

Isser Elishis, Chief Investment Officer of Waterton Global Resource
Management, commented: “We are extremely pleased that both ISS and Glass
Lewis have supported our case for change to the Hudbay Board. Waterton
continues to believe our nominees have the right experience and
expertise to help Hudbay unlock its significant potential and urges
shareholders to vote FOR the election of all four of our nominees –
Peter Kukielski, Richard Nesbitt, Daniel Muniz Quintanilla and David
Smith. We are confident our nominees are well-positioned to provide
Hudbay with the best opportunity for long-term value creation.”

Waterton urges shareholders to vote for the Waterton Nominees on the BLUE
form of proxy and/or BLUE voting
instruction form by 5:00 p.m. (Eastern time) on
Thursday, May 2, 2019
. Shareholders willing to express their
support for the Waterton Nominees may contact Kingsdale Advisors, our
strategic shareholder advisor and proxy solicitation agent, at
1-888-518-1563 toll-free in North America, or at 416-867-2272 outside of
North America (collect calls accepted), or by email at [email protected].

Visit www.NewHudbay.com
for additional information.

About Waterton

Waterton is an investment firm that manages capital for global
institutional investors, sovereign wealth funds and endowments. The firm
has ~US$2 billion in assets under management and focuses solely on the
metals and mining sector. Waterton has a culture of thoroughness and a
disciplined approach to capital allocation, and utilizes its significant
industry expertise to produce out-sized risk-adjusted returns.

Legal Notices and Disclaimers

The data, information and opinions contained or referenced herein
(collectively, the “Information”) is for general informational purposes
only for the holders of Shares (“Shareholders”) in order to provide the
views of Waterton regarding certain changes we are requesting to the
composition of the Board, and other matters which Waterton believes to
be of concern to Shareholders described herein. The Information is not
tailored to specific investment objectives, the financial situation,
suitability, or particular need of any specific person(s) who may
receive the Information, and should not be taken as advice in
considering the merits of any investment decision. The views expressed
in the Information represent the views and opinions of Waterton, whose
opinions may change at any time and which are based on analyses of
Waterton and its advisors. Unless otherwise indicated, the Information
has been derived or obtained from public disclosure and filings with
respect to and/or made by Hudbay and other issuers that we consider to
be comparable to Hudbay, and from other third party reports (see “Legal
Notices and Disclaimers – Disclaimer Respecting Publicly Sourced
Information” in Waterton’s information circular dated April 15, 2019
(the “Waterton Circular”), a copy of which is available on SEDAR at www.sedar.com
or on www.newhudbay.com).

The Information contains forward-looking statements or forward-looking
information within the meaning of applicable securities laws
(collectively, “forward-looking statements”), including, without
limitation, Waterton’s and Hudbay’s respective priorities, plans and
strategies for Hudbay and certain members of Hudbay’s operational,
compensation and other noted peer groups’ anticipated financial and
operating performance and business prospects. All statements and
information, other than statements of historical fact, included herein
are forward-looking statements, including, without limitation,
statements regarding activities, events or developments that Waterton
expects or anticipates may occur in the future. Certain forward-looking
statements contained herein may be considered to be future-oriented
financial information or a financial outlook for the purposes of
applicable securities laws. These forward-looking statements can be
identified by the use of forward-looking words such as “will,” “expect,”
“intend,” “plan,” “estimate,” “anticipate,” “believe” or “continue” or
similar words and expressions or the negative thereof. There can be no
assurance that the plans, intentions or expectations upon which these
forward-looking statements are based will occur or, even if they do
occur, will result in the performance, events or results expected.

We caution readers not to place undue reliance on forward-looking
statements contained herein, which are not a guarantee of performance,
events or results and are subject to a number of known and unknown risks
and uncertainties, including but not limited to those set forth in the
Waterton Circular under the heading “Legal Notices and Disclaimers –
Forward-Looking Statements” and those risks and uncertainties detailed
in the continuous disclosure and other filings of Hudbay and certain
members of Hudbay’s operational, compensation and other noted peer
groups with applicable securities regulators, copies of which are
available on SEDAR at www.sedar.com
or on the Electronic Data Gathering, Analysis, and Retrieval at www.sec.gov.
We urge you to carefully consider those risks and uncertainties. The
forward-looking statements contained herein are expressly qualified in
their entirety by this cautionary statement. Unless expressly stated
otherwise, the forward-looking statements included herein are made as of
the date hereof and Waterton disclaims any obligation to publicly update
such forward-looking statements, except as required by applicable law.

_______________________________
1 Permission to quote
ISS was neither sought nor obtained. Emphasis added.
2
Permission to quote Glass Lewis was neither sought nor obtained.
Emphasis added.

Contacts

Investors
Kingsdale Advisors
Toll-Free (within North
America): 1-888-518-1563
Call Collect (outside North America):
1-416-867-2272
E-mail: [email protected]

Media
Sloane & Company
Dan Zacchei / Joe Germani:
1-212-486-9500
E-mail: [email protected]
/ [email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand

Published

on

Continue Reading

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

on

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the  seller.

“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to,  the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html

Continue Reading

Cannabis

Right on Brands Announces Major Product Line Expansion via HONEY® Brands

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania